Document:

EXHIBIT 10.67

TERMINATION AGREEMENT

          This
TERMINATION AGREEMENT is entered into this December [30] , 2004, between
VaxGen, Inc., a Delaware corporation (“VaxGen”), and Celltrion, Inc., a corporation
organized under the laws of the Republic of Korea (“Celltrion,” and together with VaxGen, the
“Parties,” and each a “Party”).

Recitals

          WHEREAS,
the Parties are party to a Supply Agreement (the “Supply Agreement”), a License Agreement (the “License
Agreement”), and a Sub-License
Agreement (the “Sub-License Agreement”),
each dated March 25, 2002 (collectively, the “Collateral
Agreements”).

          WHEREAS,
effective as of the date hereof, the Parties desire to terminate the Collateral
Agreements in their entirety, including, without limitation, any provisions
thereof that purport to survive a termination thereof, such that the Collateral
Agreements shall no longer have any force or effect.

          NOW,
THEREFORE, in consideration of the mutual premises, agreements and covenants
set forth herein, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Parties hereto, intending
legally to be bound, hereby agree as follows:

Terms of Agreement

1.       Termination of Supply Agreement. The
Parties hereby terminate the Supply Agreement in its entirety, including,
without limitation, any provisions thereof that purport to survive a
termination thereof, and agree that the Supply Agreement no longer has any
force or effect. 

2.       Termination of License Agreement. The
Parties hereby terminate the License Agreement in its entirety, including,
without limitation, any provisions thereof that purport to survive a
termination thereof, and agree that the License Agreement no longer has any
force or effect.

3.       Termination of Sub-License Agreement. The
Parties hereby terminate the Sub-License Agreement in its entirety, including,
without limitation, any provisions thereof that purport to survive a
termination thereof, and agree that the Sub-License Agreement no longer has any
force or effect.

4.       Termination of Other Agreements. The
Parties hereby terminate any and all agreements or understandings, whether oral
or written, entered into between them prior to the date hereof, in their
entirety, including, without limitation, any provisions thereof that purport to
survive a termination thereof, and agree that such agreements or understandings
shall not longer have force or effect; provided, however, that this Section 4 shall not apply to (a) that
certain

Assignment
Agreement, dated as of March 25, 2002, between the Parties, and (b) the VCI
Agreements (as defined below). As used herein, the term “VCI Agreements” shall mean any agreement or
understanding, whether oral or written, between the Parties and relating to
VaxGen-Celltrion, Inc., a California corporation (“VCI”), including, but not limited to, that certain Joint
Venture Agreement dated June 7, 2002. The termination of the VCI Agreements
shall be governed by a letter agreement (relating to the agreement by VaxGen to
purchase shares of common stock of VCI, held
by Celltrion) entered into between the Parties on even date herewith.

5.       Waiver and Release of Claims. 

          5.1
      Waiver and Release. Each Party
hereby fully and forever releases and discharges the other Party, together with
any and all of the other Party’s present or former agents, stockholders,
directors, officers, employees, principals, successors and assigns
(collectively the “Released Parties”),
from and against any and all claims, actions, suits, causes of action,
judgments, liens, promises, executions, debts, damages, demands, liabilities
and controversies whatsoever, or every nature and description, in law or in
equity, whether known or unknown and whether arising by statute, at common law
or otherwise, which such Party ever had or now has against the Released
Parties, from the beginning of the world to the date of this Agreement, and
which arise out of, or relate to, any or all of the Collateral Agreements,
including, but not limited to, for any inaccurate representation or breach of
any warranty or covenant.

          5.2
      Acknowledgement. Each Party represents and warrants to the other Party that
it (a) has read and understands this Agreement, including the release
set forth in Section 5.1, and has entered into it voluntarily and without
coercion; (b) has been advised, and has
had the opportunity, to consult with legal counsel of its choosing with respect
to this Agreement and the matters contemplated hereby; (c) is entering into
this Agreement based upon its own investigation and is not relying on any
representations or warranties of the other Party or any other person not set
forth herein; (d) has not assigned or otherwise transferred any interest
in any claim which it may have against any Released Parties; and (e) acknowledges that it is entering
into this Agreement with full knowledge and understanding that in exchange for
the benefits to be received as described herein, it is giving up certain
valuable rights that he or she may now have or may later acquire, including,
but not limited to, his or her rights under the Collateral Agreements, and is
fully and completely waiving any and all rights which he or she has or may
have, under California Civil Code Section 1542, which states: 

	
 

	
 

	
 

	
 

	
“A general release does not extend to claims which the creditor does
  not know or suspect to exist in his favor at the time of executing the
  release, which if known to him must have materially affected his settlement
  with the debtor.”

	
 

6.
     Effectiveness. This Agreement
shall be effective on the date on which the following three (3) conditions are
satisfied: (a) it has been executed and delivered by the Parties, (b) the
Parties have executed and delivered that certain (i) Technical Support &
Services Agreement and (ii) letter agreement (relating to the agreement by
VaxGen to purchase shares of common stock of VCI held by Celltrion), each dated
on even date herewith, and (c) that certain Amended and Restated Joint Venture
Agreement, among VaxGen, Nexol Biotech Co., Ltd., a corporation 

2

organized under the laws
of the Republic of Korea, Nexol Co., Ltd., a corporation organized under the
laws of the Republic of Korea, KT&G Corporation (formerly Korea Tobacco
& Ginseng Corporation), a corporation organized under the laws of the
Republic of Korea, and J. Stephen & Company Ventures Ltd., a corporation
organized under the laws of the Republic of Korea, is executed and delivered by
the parties thereto.

7.       General Provisions.

          7.1
  Notices. All notices, requests, demands,
claims, and other communications permitted or required to be given under this
Agreement shall be in writing. Any such notice, request, demand, claim, or
other communication shall be deemed duly given and received (a) when delivered
personally to the recipient, (b) one (1) business day after being sent to the
recipient by reputable overnight courier service, charges prepaid, (c) one (1)
business day after being sent to the recipient by facsimile transmission or
electronic mail (with electronic verification of its transmission), or (d) four
(4) business days after being mailed to the recipient by certified or
registered mail, return receipt requested and postage prepaid, and addressed to
the intended recipient as set forth below:

	
 

	
 

	
 

	
 

	
(a)

	
If to
  VaxGen:

	
 

	
 

	
 

	
 

	
 

	
VaxGen, Inc.

  1000 Marina Boulevard

  Brisbane, California 94005-1841

  Attention: Dr. Lance K. Gordon, CEO

  Facsimile: (650) 624-1001

  Email: lgordon@vaxgen.com

	
 

	
 

	
 

	
 

	
(b)

	
If to
  Celltrion:

	
 

	
 

	
 

	
 

	
 

	
Celltrion,
  Inc.

  1001-5, Dongchun-Dong, Yeonsu-Gu

  Incheon City, 406-130, Korea

  Attention: Jung-Jin, Seo

  Facsimile: 82-32-850-5040

  Email: jjseo@celltrion.com

          7.2
  Counterparts; Facsimile Signatures.
This Agreement may be executed in one or more counterparts and by facsimile
signature, each of which shall be considered an original and all of which,
together, shall be deemed one and the same agreement.

          7.3
  Entire Agreement. This Agreement
constitutes the entire agreement between the Parties with respect to the
subject matter hereof, and supersede all prior and contemporaneous agreements
and understandings of the Parties with respect thereto, whether oral or
written.

          7.4
   Severability. In the event that
any provision of this Agreement, or the application thereof, becomes or is
declared by a court of competent jurisdiction to be illegal, void or
unenforceable, the remainder of this Agreement will continue in full force and
effect. The Parties further agree to replace such void or unenforceable
provision of this Agreement with a 

3

valid and enforceable
provision that will achieve, to the extent possible, the economic, business and
other purposes of such void or unenforceable provision.

          7.5
   Governing Law; Consent to Jurisdiction.
This Agreement shall be governed by, and construed in accordance with, the laws
of the State of California without regard to principles of conflicts of law.
Any proceeding which arises out of or relates in any way to the subject matter
of this Agreement shall be brought in the Superior Court of California, County
of San Francisco, or the United States District Court for the Northern District
of California. The Parties hereby consent to the jurisdiction of the State of
California and the United States of America, and waive their right to challenge
any proceeding involving or relating to this Agreement on the basis of lack of
jurisdiction over the person or forum non conveniens.

          7.6
   Assignment. Neither Party to this
Agreement may assign this Agreement or any of its rights, interests, or
obligations hereunder. 

          7.7
   Waiver. Any term of this Agreement
or the performance thereof may only be waived in writing by the Party entitled
to the benefit or performance of such term. 

          7.8
   Amendments. This Agreement may not
be amended except in writing signed by the Parties. 

          7.9
   Successors and Assigns. The terms
and conditions of this Agreement shall inure to the benefit of, and be binding
upon, the respective successors and permitted assigns of the Parties. Nothing
in this Agreement, express or implied, is intended to confer upon any Party,
other than the Parties hereto or their respective successors and permitted
assigns, any rights, remedies, obligations, or liabilities under, or by reason
of, this Agreement, except as expressly provided in this Agreement.

          7.10
  Titles and Subtitles. The titles
and subtitles used in this Agreement are used for convenience only and are not
to be considered in construing or interpreting this Agreement.

          7.11
  Further Assurances. Each Party to
this Agreement shall take all actions and execute all documents reasonably
necessary to effectuate the purposes and intents of this Agreement.

          IN
WITNESS WHEREOF, the Parties have executed this Agreement as of the date first
written above.

	
 

	
 

	
 

	
 

	
 

	
CELLTRION, INC.

	
 

	
VAXGEN, INC.

	
 

	
 

	
 

	
 

	
 

	
By:

	
/s/ Jung-Jin
  Seo

	
 

	
By:

	
/s/ Lance
  Gordon

	
 

	

	
 

	
 

	

	
 

	
Name: Jung-Jin Seo

	
 

	
 

	
Name: Dr.
  Lance Gordon

	
 

	
Title: CEO & Representative Director

	
 

	
 

	
Title: Chief
  Executive Officer

4EXHIBIT 10.68

          This AGREEMENT
(this “Agreement”)
is entered into as of the [30th] day of [December], 2004, by and among VaxGen,
Inc., a Delaware corporation (“VaxGen”), Nexol Biotech Co., Ltd., a
corporation organized under the laws of the Republic of Korea (“Nexol”),
Nexol Co., Ltd., a corporation organized under the laws of the Republic of
Korea (“Nexol
Co”), KT&G Corporation (formerly Korea Tobacco & Ginseng
Corporation), a corporation organized under the laws of the Republic of Korea (“KT&G”),
J. Stephen & Company Ventures Ltd., a corporation organized under the laws
of the Republic of Korea (“JS”) and Celltrion, Inc., a corporation
organized under the laws of the Republic of Korea (“Celltrion,” and together with VaxGen, Nexol, Nexol Co,
KT&G, and JS, the “Parties” and each a “Party”). 

RECITALS

          WHEREAS,
the Parties (other than Celltrion) are
parties to a Joint Venture Agreement,
dated February 25, 2002, which agreement was amended by a certain Amendment to
Joint Venture Agreement dated July 14, 2004 (as so amended, the “Prior JVA”). 

          WHEREAS,
pursuant to the Prior JVA, Celltrion has issued to VaxGen 7,800,000 Common
Shares in exchange for the agreement by VaxGen to contribute to Celltrion
certain technology, which the Parties valued at US $30,000,000 at the time the
Common Shares were issued.

          WHEREAS,
concurrently with the execution and delivery of this Agreement (a) VaxGen and
Celltrion are entering into a certain Termination Agreement (the “Termination
Agrement”), pursuant to which certain agreements, including, but not limited
to, a Supply Agreement, a License Agreement (the “License Agreement”), and a
Sub-License Agreement (the “Sub-License Agreement”), each dated March 25, 2002,
will terminate and no longer have any force or effect, and (b) the Parties
(other than Celltrion) are entering into an Amended and Restated Joint Venture
Agreement (the “Amended JVA”), pursuant to which the Prior JVA will be amended
and restated in its entirety. 

          WHEREAS,
under the Prior JVA, JS has an obligation to invest in Celltrion (a)
9,750,000,000 Won in cash, in return for 1,950,000 preferred shares of
Celltrion at the price of 5,000 Won per share and (b) an additional
9,750,000,000 Won in return for 390,000 preferred shares of Celltrion at the
premium price of 25,000 Won per share. As of the date hereof, JS has invested (i)9,750,000,000 Won in exchange for
1,950,000 preferred shares of Celltrion at the price of 5,000 Won per share and
(ii) 4,875,000,000 Won in exchange for 195,000 preferred shares of Celltrion at
the price of 25,000 Won per share. Accordingly, JS has failed to subscribe for
195,000 preferred shares of Celltrion at the price of 25,000 Won per share in
accordance with the Prior JVA;

          WHEREAS,
as a result of the foregoing, the Parties have determined that it is fair and
equitable for VaxGen and JS to surrender a portion of their shares in Celltrion,
in exchange for a release of liability as further described herein.

          NOW,
THEREFORE, in consideration of the mutual promises and agreements contained
herein as well as for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the
Parties hereby agree as follows: 

1.       VaxGen’s Surrender
of 2,000,000 Common Shares. In consideration for the release
described in Section 3, VaxGen hereby agrees to surrender to Celltrion any and
all rights it may have in 2,000,000 of its Common Shares of Celltrion, and
shall deliver to Celltrion for cancellation the certificates representing such
shares. VaxGen’s
surrender of 2,000,000 shares shall be in consideration of the termination of
the License Agreement and Sub-License Agreement referred to in the Recitals
above, under which VaxGen would otherwise have certain ongoing future
obligations to Celltrion. The Parties acknowledge and agree that
immediately following the surrender described in this Section 1, the total
number of Common Shares in Celltrion owned by VaxGen shall be 5,800,000.

2.       JS’s Surrender
of 338,919 Preferred Shares. JS hereby agrees to surrender to Celltrion any and all rights it may
have in 338,919 preferred shares of Celltrion, and shall deliver to Celltrion
for cancellation the certificates representing such shares. The Parties
acknowledge and agree that immediately following the surrender described in
this Section 2, the total number of preferred shares in Celltrion owned by JS
shall be 1,706,081, excluding 100,000 preferred shares transferred to third
party on December 31, 2002.

3.       Waiver and Release of
VaxGen.

          3.1       Upon
the surrender by VaxGen of the Common Shares in accordance with Section 1
above, each Party (other than VaxGen) fully and forever releases and discharges
VaxGen, together with any and all of its present or former agents,
stockholders, directors, officers, employees, principals, successors and
assigns (collectively the “VaxGen Released Parties”),
from and against any and all claims, actions, suits, causes of action,
judgments, liens, promises, executions, debts, damages, demands, liabilities
and controversies whatsoever, or every nature and description, in law or in
equity, whether known or unknown and whether arising by statute, at common law
or otherwise, which any such Party ever had or now has against the VaxGen Released Parties, from the
beginning of the world to the date of this Agreement, and which arise out of,
or relate to, any obligation VaxGen may have had to contribute technology to
Celltrion, whether pursuant to the Prior JVA, the Contribution Agreement,
entered into among the Parties (other than Celltrion) on February 25, 2002, or
otherwise.

          3.2
      Acknowledgement.
Each Party (other than VaxGen) represents
and warrants to VaxGen that it (a) has read and understands this
Agreement, including the release set forth in Section 3.1, and has entered into
it voluntarily and without coercion; (b)
has been advised, and has had the opportunity, to consult with legal counsel of
its choosing with respect to this Agreement and the matters contemplated
hereby; (c) is entering into this Agreement based upon its own investigation
and is not relying on any representations or warranties of the other Parties or
any other person not set forth herein; (d) has not assigned or otherwise
transferred any interest in any claim which it may have against any VaxGen Released
Parties; and (e) acknowledges that

2

it is entering
into this Agreement with full knowledge and understanding that in exchange for
the benefits to be received as described herein, it is giving up certain
valuable rights that it may now have or may later acquire, and is fully and
completely waiving any and all of such rights. 

4.       Waiver and Release of
JS.

          4.1
      Upon the surrender by JS of the preferred shares in
accordance with Section 2 above, the Parties (other than JS)fully and
forever release and discharge JS, together with
any and all of its present or former agents, stockholders, directors, officers,
employees, principals, successors and assigns (collectively the “JS Released Parties”), from and against any and
all claims, actions, suits, causes of action, judgments, liens, promises,
executions, debts, damages, demands, liabilities and controversies whatsoever,
or every nature and description, in law or in equity, whether known or unknown
and whether arising by statute, at common law or otherwise, which any such
Party ever had or now has against the JS Released
Parties, from the beginning of the world to the date of this Agreement, and
which arise out of, or relate to, any obligation JS may have had to invest the amount it
committed to invest in
Celltrion pursuant to the Prior JVA.

          4.2
      Acknowledgement. Each Party (other than JS) represents
and warrants to JS that it (a) has read
and understands this Agreement, including the release set forth in Section 4.1, and has entered into it voluntarily
and without coercion; (b) has been
advised, and has had the opportunity, to consult with legal counsel of its
choosing with respect to this Agreement and the matters contemplated hereby;
(c) is entering into this Agreement based upon its own investigation and is not
relying on any representations or warranties of the other Parties or any other
person not set forth herein; (d) has not assigned or otherwise
transferred any interest in any claim which it may have against any JS Released Parties; and (e) acknowledges that it is entering
into this Agreement with full knowledge and understanding that in exchange for
the benefits to be received as described herein, it is giving up certain
valuable rights that it may now have or may later acquire, and is fully and
completely waiving any and all of such rights.

5.       Effectiveness. This Agreement shall be effective on the date on which the following
three (3) conditions are satisfied: (a) it has been executed and delivered by
the Parties, (b) the Parties (other than Celltrion) have executed and delivered
the Amended JVA, and (c) VaxGen and Celltrion have executed and delivered (i)
the Termination Agreement, (ii) that certain Technical Support & Services
Agreement, and (iii) that certain letter agreement (relating to the agreement
by VaxGen to exercise its option to purchase shares of common stock of
VaxGen-Celltrion, Inc., a California corporation, held by Celltrion), each
dated on even date herewith.

6.       Indemnification.
Celltrion shall hold VaxGen and its directors, officers, employees, agents,
affiliates and other representatives (the “VaxGen Indemnified Parties”)
harmless from, and shall indemnify and defend the VaxGen Indemnified Parties
from and against, any and all obligations, judgments, liabilities, penalties,
violations, fees, fines, claims, losses, costs, demands, damages, liens,
encumbrances and expenses, including, but not limited to, reasonable attorneys’
fees (collectively, “Damages”) in respect of any and all federal, state, local,
or foreign taxes of whatever kind in the jurisdiction of the Republic of Korea (including penalties
thereon, “Taxes”), to the extent such Taxes arise out of, are related to, or
are a consequence of, the surrender of the Common Shares as contemplated by
this Agreement.

3

7.       Other Provisions. 

          
7.1 Notices.
All notices, requests, demands, claims,
and other communications permitted or required to be given under this Agreement
shall be in writing. Any such notice, request, demand, claim, or other
communication shall be deemed duly given and received (a) when delivered
personally to the recipient, (b) one (1) business day after being sent to the
recipient by reputable overnight courier service, charges prepaid, (c) one (1)
business day after being sent to the recipient by facsimile transmission or
electronic mail (with electronic verification of its transmission), or (d) four
(4) business days after being mailed to the recipient by certified or
registered mail, return receipt requested and postage prepaid, and addressed to
the intended recipient as set forth below:

	
 

	
 

	
 

	
 

	
(a)

	
If to
  VaxGen:

	
 

	
 

	
 

	
 

	
 

	
VaxGen, Inc.

1000 Marina Boulevard

Brisbane, California 94005-1841

Attention: Dr. Lance K. Gordon, CEO

Facsimile: (650) 624-1001

Email: lgordon@vaxgen.com 

	
 

	
 

	
 

	
 

	
(b)

	
If to JS:

	
 

	
 

	
 

	
 

	
 

	
J. Stephen
  & Company Ventures Ltd.

  23rd Fl., City Air Tower

  159-9 Samsung-dong

  Kangnam-ku, Seoul, Republic of Korea

  Attention: Mr. Taxun Synn

  Facsimile: 82-2-2016-6509

  Email: t.synn@jstephenco.com

	
 

	
 

	
 

	
 

	
(a)

	
If to Nexol:
  

	
 

	
 

	
 

	
 

	
 

	
Hanyang
  Securities Co., Ltd. Bldg., Suite 300, 

  17-3, Youido-dong, Youngdeungpo-ku, Seoul, Republic of Korea

  Fax No: 82-2-786-6776

  Attention: Mr. Hyoung-Ki Kim

	
 

	
 

	
 

	
 

	
(b)

	
If to Nexol
  Co:

	
 

	
 

	
 

	
 

	
 

	
Hanyang
  Securities Co., Ltd. Bldg., Suite 300, 

	
 

	
 

	
17-3,
  Youido-dong, Youngdeungpo-ku, Seoul, Republic of Korea

	
 

	
 

	
Fax No:
  82-2-786-6776

	
 

	
 

	
Attention:
  Mr. Hyoung-Ki Kim

4

	
 

	
 

	
 

	
 

	
(c)

	
If to
  KT&G:

	
 

	
 

	
 

	
 

	
 

	
100,
  Pyungchon-dong, Daeduk-gu, Daejon, Republic of Korea

  Fax No: 82-2-3404-4670

  Attention: Mr. Sang-Seock Kim

	
 

	
 

	
 

	
 

	
(d)

	
If to Celltrion:

	
 

	
 

	
 

	
 

	
 

	
1001-5, Dongchun-dong, Yeonsu-gu 

  Incheon, 406-130,
  Republic of Korea

  Fax No: 82-32-850-5040

  Attention: Mr. Jung-Jin Seo, CEO

8.       Counterparts; Facsimile Signatures.
This Agreement may be executed in one or more counterparts and by facsimile
signature, each of which shall be considered an original and all of which,
together, shall constitute one and the same instrument.

9.       Entire Agreement. This
Agreement constitutes the entire agreement among the Parties with respect to
the subject matter hereof, and supersedes all prior and contemporaneous
agreements and understandings of the Parties with respect thereto, whether oral
or written.

10.     Severability. In the event
that any provision of this Agreement or the application thereof, becomes or is
declared by a court of competent jurisdiction to be illegal, void or
unenforceable, the remainder of this Agreement will continue in full force and
effect. The Parties further agree to replace such void or unenforceable
provision of this Agreement with a valid and enforceable provision that will
achieve, to the extent possible, the economic, business and other purposes of
such void or unenforceable provision.

11.     Governing Law; Consent to Jurisdiction.
This Agreement shall be governed by, and construed in accordance with, the laws
of the Republic of Korea. The Parties hereby agree that any and all dispute,
controversies, and claims between or among them that arise out of this
Agreement shall be resolved in accordance with Section 13.1 of the Amended JVA.

12.     Assignment. No Party may
assign this Agreement or any of its rights, interests, or obligations
hereunder. 

13.     Waiver. Any term of this
Agreement or the performance thereof may only be waived in writing by the Party
entitled to the benefit or performance of such term. 

14.     Amendments. This Agreement
may not be amended except in writing signed by the Parties. 

15.     Successors
and Assigns. The terms and conditions of this Agreement shall inure to the
benefit of, and be binding upon, the respective successors and permitted
assigns of the Parties. Nothing in this Agreement, express or implied, is
intended to confer upon any party, other than 

5

the Parties or
their respective successors and permitted assigns, any rights, remedies,
obligations, or liabilities under, or by reason of, this Agreement, except as
expressly provided in this Agreement.

16.     Titles and Subtitles. The
titles and subtitles used in this Agreement are used for convenience only and
are not to be considered in construing or interpreting this Agreement.

17.     Further Assurances. Each Party
to this Agreement shall take all actions and execute all documents reasonably
necessary to effectuate the purposes and intents of this Agreement.

          IN
WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed
by their respective representatives thereunto duly authorized as of the date
first hereinabove set forth.

	
 

	
 

	
 

	
 

	
 

	
VAXGEN, INC.

	
 

	
KT&G CORPORATION

	
 

	
 

	
 

	
 

	
 

	
By:

	
/s/ Lance Gordon 

	
 

	
By:

	
/s/ Young-Kyoon Kwak 

	
 

	

	
 

	
 

	

	
 

	
Name: Dr. Lance Gordon

	
 

	
 

	
Name: Mr. Young-Kyoon Kwak

	
 

	
Title: Chief Executive
  Officer

	
 

	
 

	
Title: President & CEO

	
 

	
 

	
 

	
 

	
 

	
NEXOL CO., LTD.

	
 

	
NEXOL BIOTECH CO., LTD.

	
 

	
 

	
 

	
 

	
By:

	
/s/ Jung-Jin Seo 

	
 

	
By:

	
/s/ Jung-Jin Seo 

	
 

	

	
 

	
 

	

	
 

	
Name: Mr. Jung-Jin Seo

	
 

	
 

	
Name: Mr. Jung-Jin Seo

	
 

	
Title: Representative
  Director

	
 

	
 

	
Title: Representative
  Director

	
 

	
 

	
 

	
 

	
 

	
J. STEPHEN & COMPANY VENTURES LTD.

	
 

	
CELLTRION,
  INC.

	
 

	
 

	
 

	
 

	
 

	
By:

	
/s/ Sun-Dae Kang 

	
 

	
By:

	
/s/ Jung-Jin Seo

	
 

	

	
 

	
 

	

	
 

	
Name: Mr. Sun-Dae Kang

	
 

	
 

	
Name: Mr. Jung-Jin Seo

	
 

	
Title: CEO & Chairman

	
 

	
 

	
Title: CEO &
  Representative Director

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}]]